Folate and pyridoxine to ssri in major depression and residual cognitive Decline - 08/07/17
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 2 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Résumé |
Introduction |
Depressive disorders are very common conditions, lifetime risk for experiencing major depression is approximately 15%.
Objective |
Patients with major depression having an insufficient response to SSRI may benefit from addition of methylfolate and pyridoxine.
Aim |
The aim of our study was to determine the effect of folate and pyridoxine augmentation to SSRI on emotional, physical and cognitive symptoms in major depression.
Methods |
Eighteen patients with MDD were enrolled, were on citalopram 20mg/day when folate/15mg per day/and pyridoxine/40mg per day/were added. They have been monitored for three months using standard scales for depression and assessment by interview.
Results |
After three months of using folate and pyridoxine to SSRI there was a significant improvement in depression as measured by the scales. In 8 patients were recorded improvements of 30–50%. The most prominent changes were in cognitive sphere of depression such as attention, reasoning and problem solving, working memory and speed of processing.
Conclusion |
Low levels of folate and pyridoxine have been associated with the presence of depression and residual poor cognitive function. Our study confirms that folate and pyridoxine as adjunctive therapy to SSRI-partially refractory major depression is useful in particular to issues of residual cognitive interference conditions such as impaired concentration and memory, slow mentation, attention/vigilance, problem solving, working memory and speed of processing.
Le texte complet de cet article est disponible en PDF.Plan
Vol 41 - N° S
P. S541-S542 - avril 2017 Retour au numéro
Article précédent
- An item response theory based analysis of the Hamilton depression rating scale-an Indian perspective
- D. Sanyal, B. Mukherjee
- Clinical and neurocognitive characteristics associated with treatment-resistant depression
- G. Serafini, G. Adavastro, G. Canepa, C. Conigliaro, M. Pompili, P. Girardi, M. Amore
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?